Best of ASCO - 2014 Annual Meeting

 

Welcome

Conduct of Clinical Research

Developmental Immunotherapy and Tumor Immunobiology

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A relationship-based approach to improving the clinical trial experience.

Sarah MacKay Helou

e14055

An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic triple-negative breast cancer (mTNBC).

Steven O'Day

2550

Association of efficacy of anti-PD-1 immunotherapy in patients with advanced cancer with immune-related adverse events (irAEs).

Jacobo Rogado Revuelta

e14064

Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients.

Maneet Multani

e14061

Community and academic partnerships: Moving a new generation of clinical trials in NCI community oncology research program (NCORP) into community oncology practices.

Worta J. McCaskill-Stevens

2551

Effect of mandatory research biopsy requirements on initiation of clinical trials.

Jonathan Hin Cheng

e14057

Immune checkpoint inhibitors (ICI): An analysis of FDA’s and EMA’s decision patterns and times for initial approvals and extensions of indication.

Christine Mayer-Nicolai

e14062

Influence of agomelatine and trastuzumab on the HER2/neu(+), MT1 (+) and MT2 (+) chemo and immunoresistant breast cancer cells lines from the previously treated patients by targeted therapy with trastuzumab.

Alexandre Tavartkiladze

e14056

Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

Karen A. Autio

2548

Re-evaluating eligibility criteria: Analysis of factors leading to nonparticipation and outcomes of patients (pt) with advanced cancer who signed consent but were not treated in early-phase immunotherapy (IO) trials.

Roberto Carmagnani Pestana

2552

Revisiting the ethics of phase 1 oncology trials in the era of precision medicine: A systematic review.

Michael Patrick Mackley

e14060

Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study.

Anna Maria Di Giacomo

2549

The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.

Daniel Wilhelm Mueller

TPS2651